Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoFuse Dose-Escalation in Lumbar Fusion
NCT00549913Phase 2Completed
- Sponsor
- Mesoblast Ltd
- Start
- Oct 2007
- Primary completion
- Aug 2013
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rexlemestrocel-l in degenerative disc disease (DDD), spondylolisthesis and spinal stenosis (6 arms), sponsored by Mesoblast Ltd. Primary endpoint: Safety of NeoFuse combined with MasterGraft at 30 days. Started Oct 2007; status: completed.
02
Drugs
rexlemestrocel-l
03
Conditions
degenerative disc disease (DDD)spondylolisthesisspinal stenosis
Beyond the preview
Go deeper on NCT00549913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00549913.